Related Experiment Video
Updated: May 29, 2026
07:39
SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
Published on: June 28, 2019
Chip-based drug screening for inhibiting α-glucosidase
Chung-Chia Chen1, Ping-Hsien Chuang, Yueh-Sheng Chen
1Linsen-Chinese Medicine Branch, Taipei City Hospital, Taipei, Taiwan.
Fitoterapia
|September 13, 2011
Summary
This study introduces a new screening technology to find herbal compounds that inhibit intestinal alpha-glucosidase. This method efficiently identifies natural compounds that can help manage blood sugar levels after meals.
Area of Science:
- Biochemistry
- Pharmacology
- Natural Product Chemistry
Background:
- Intestinal alpha-glucosidase is crucial for carbohydrate digestion.
- Inhibiting alpha-glucosidase can reduce postprandial blood glucose spikes.
- Herbal medicines are a potential source for such inhibitors.
Purpose of the Study:
- To develop a novel technology for screening herbal medicines.
- To identify compounds with alpha-glucosidase-suppressing activity.
- To establish an efficient platform for drug discovery from natural products.
Main Methods:
- Development of the 'after flowing through immobilized receptor' (AFTIR) technology.
- Application of AFTIR for targeting specific components in herbal extracts.
- Purification and identification of active compounds using the AFTIR system.
Main Results:
- The AFTIR system demonstrated high efficiency in screening.
- Active components with alpha-glucosidase-suppressing capability were successfully purified.
- The platform enabled the identification of key compounds from herbal medicines.
Conclusions:
- The AFTIR system is a powerful and efficient drug screening platform.
- This technology facilitates the discovery of novel alpha-glucosidase inhibitors from herbal sources.
- AFTIR aids in identifying natural compounds for managing carbohydrate digestion and blood glucose.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...